- Home
- TRDA vs FDMT Comparison
TRDA vs FDMT Comparison
Compare TRDA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- FDMT
- Stock Information
- Founded
- TRDA 2016
- FDMT 2013
- Country
- TRDA United States
- FDMT United States
- Employees
- TRDA N/A
- FDMT N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- TRDA Health Care
- FDMT Health Care
- Exchange
- TRDA Nasdaq
- FDMT Nasdaq
- Market Cap
- TRDA 233.5M
- FDMT 192.2M
- IPO Year
- TRDA 2021
- FDMT 2020
- Fundamental
- Price
- TRDA $5.55
- FDMT $7.10
- Analyst Decision
- TRDA Strong Buy
- FDMT Buy
- Analyst Count
- TRDA 3
- FDMT 9
- Target Price
- TRDA $25.67
- FDMT $30.63
- AVG Volume (30 Days)
- TRDA 313.7K
- FDMT 515.7K
- Earning Date
- TRDA 11-04-2025
- FDMT 11-12-2025
- Dividend Yield
- TRDA N/A
- FDMT N/A
- EPS Growth
- TRDA N/A
- FDMT N/A
- EPS
- TRDA N/A
- FDMT N/A
- Revenue
- TRDA $79,476,000.00
- FDMT $33,000.00
- Revenue This Year
- TRDA N/A
- FDMT $8,572.97
- Revenue Next Year
- TRDA N/A
- FDMT N/A
- P/E Ratio
- TRDA N/A
- FDMT N/A
- Revenue Growth
- TRDA N/A
- FDMT N/A
- 52 Week Low
- TRDA $4.93
- FDMT $2.24
- 52 Week High
- TRDA $21.79
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- TRDA 52.22
- FDMT 60.19
- Support Level
- TRDA $5.08
- FDMT $6.60
- Resistance Level
- TRDA $5.49
- FDMT $7.21
- Average True Range (ATR)
- TRDA 0.30
- FDMT 0.40
- MACD
- TRDA 0.03
- FDMT -0.05
- Stochastic Oscillator
- TRDA 72.11
- FDMT 79.02
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.